LIXTE Biotechnology announced the dosing of the first patient in a new clinical trial in collaboration with the Netherlands Cancer Institute, NKI, and supported by F. Hoffmann-La Roche for treatment of unresponsive metastatic colorectal cancer. As part of the clinical trial, LIXTE is providing its lead compound, LB-100, and Roche is providing atezolizumab through the imCORE Network, a global academic-industry partnership that aims to accelerate cancer immunotherapy research through institution-sponsored studies.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LIXT: